机构：[1]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China.临床科室其他部门放疗科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[2]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.其他部门华南肿瘤学国家重点实验室中山大学肿瘤防治中心[3]Department of Orthopaedic Surgery/Orthopaedic Research Institute, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province 510080, China.外科科室骨科显微外科医学部中山大学附属第一医院[4]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China.临床科室其他部门鼻咽科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[5]Department of Pathogen Biology and Immunology, School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou 510006, China.[6]Department of Biochemistry, hongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
Background: Thymosin beta 10 (TMSB10) has been demonstrated to be involved in the malignant process of many cancers. The purpose of this study was to determine the biological roles and clinical significance of TMSB10 in breast cancer and to identify whether TMSB10 might be used as a serum marker for the diagnosis of breast cancer. Methods: TMSB10 expression was evaluated by immunohistochemical analysis (IHC) of 253 breast tumors and ELISA of serum from 80 patients with breast cancer. Statistical analysis was performed to explore the correlation between TMSB10 expression and clinicopathological features in breast cancer. Univariate and multivariate Cox regression analysis were performed to examine the association between TMSB10 expression and overall survival and metastatic status. In vitro and in vivo assays were performed to assess the biological roles of TMSB10 in breast cancer. Western blotting and luciferase assays were examined to identify the underlying pathway involved in the tumor-promoting role of TMSB10. Results: We found TMSB10 was upregulated in breast cancer cells and tissues. Univariate and multivariate analysis demonstrated that high TMSB10 expression significantly correlated with clinicopathological features, poor prognosis and distant metastases in patients with breast cancer. Overexpression of TMSB10 promotes, while silencing of TMSB10 inhibits, proliferation, invasion and migration of breast cancer cells in vitro and in vivo. Our results further reveal that TMSB10 promotes the proliferation, invasion and migration of breast cancer cells via AKT/FOXO signaling, which is antagonized by the AKT kinase inhibitor perifosine. Importantly, the expression of TMSB10 is significantly elevated in the serum of patients with breast cancer and is positively associated with clinical stages of breast cancer. Conclusion: TMSB10 may hold promise as a minimally invasive serum cancer biomarker for the diagnosis of breast cancer and a potential therapeutic target which will facilitate the development of a novel therapeutic strategy against breast cancer.
基金：
This study was supported by the Ministry of Science and Technology of China
grant (973 Program, number 2014CB910604); the Natural Science Foundation
of China (81530082, 81372814, 81572848, 81325013, 91529301); the Ministry of
Education of China (20130171110085); the Science and Technology of
Guangdong Province (No. 2014A030313220; No. 2014A020212528, No.
2014A030313008); and the Science and Technology of Guangzhou City
(No. 15020077; No. 2014 J4100181); National Science and Technique Major
Project (No. 201305017).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|2 区肿瘤学
第一作者：
第一作者机构：[2]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong 510060, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Xin Zhang,Dong Ren,Ling Guo,et al.Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer[J].BREAST CANCER RESEARCH.2017,19(1):-.doi:10.1186/s13058-016-0785-2.
APA：
Xin Zhang,Dong Ren,Ling Guo,Lan Wang,Shu Wu...&Zhenyu He.(2017).Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.BREAST CANCER RESEARCH,19,(1)
MLA：
Xin Zhang,et al."Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer".BREAST CANCER RESEARCH 19..1(2017):-
